You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

inotuzumab ozogamicin

Showing 26 - 50 of 117
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP) Trial in France

Unknown status
  • Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP)
  • Inotuzumab ozogamicin (INO)
  • Amiens, France
  • +34 more
Aug 10, 2020

Acute Lymphoblastic Leukemia in Remission, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia

Terminated
Has Results
  • Acute Lymphoblastic Leukemia in Remission
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Mar 18, 2021

B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma Trial in Houston (biological, drug, other)

Recruiting
  • B Acute Lymphoblastic Leukemia
  • B Lymphoblastic Lymphoma
  • Blinatumomab
  • +12 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 21, 2021

Reporting of Antibody-Drug Conjugate Associated Sepsis-related

Completed
  • Sepsis (SMQ)
  • +2 more
  • Antibody-Drug Conjugate
  • Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
  • Changsha, Hunan, China
    Central South University
Jun 19, 2022

Lymphoma, B-Cell Trial in Worldwide (inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone, inotuzumab

Completed
Has Results
  • Lymphoma, B-Cell
  • inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone
  • inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone
  • Gainesville, Florida
  • +27 more
Jun 13, 2019

Lymphoma, B-Cell Trial in Aichi, Kanagawa, Tokyo (Inotuzumab Ozogamicin (CMC-544), Rituximab (Rituxan))

Completed
Has Results
  • Lymphoma, B-Cell
  • Inotuzumab Ozogamicin (CMC-544)
  • Rituximab (Rituxan)
  • Aichi, Japan
  • +3 more
Dec 4, 2018

Pediatric and Young Adult B-Cell Malignancies After Commercially

Not yet recruiting
  • Lymphoid Leukemia
  • Questionnaire for patients receiving therapy
  • Palo Alto, California
    Stanford University
May 9, 2023

Leukemia, Acute Lymphoblastic Trial in Worldwide (Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab

Recruiting
  • Leukemia, Acute Lymphoblastic
  • Omitted Doxorubicin
  • +5 more
  • Brussels, Belgium
  • +100 more
Dec 12, 2022

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 Trial in Israel, United States (Blinatumomab,

Recruiting
  • B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
  • Blinatumomab
  • +10 more
  • Anchorage, Alaska
  • +152 more
Aug 11, 2022

Cancer Target Therapy Efficacy

Active, not recruiting
  • Cancer
  • RNA sequencing
  • +5 more
  • Walnut, California
  • +6 more
Sep 13, 2021

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Baltimore, Buffalo (Gemtuzumab Ozogamicin,

Recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Gemtuzumab Ozogamicin
  • +4 more
  • Baltimore, Maryland
  • +1 more
Dec 13, 2022

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk

Recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +5 more
  • Gemtuzumab Ozogamicin
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

Acute Myeloid Leukemia Trial in Baltimore (Dose Escalation -tagraxofusp-erzs, Dose Expansion at RP2D -tagraxofusp-erzs)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Dose Escalation -tagraxofusp-erzs
  • Dose Expansion at RP2D -tagraxofusp-erzs
  • Baltimore, Maryland
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Jan 27, 2023

Acute Myeloid Leukemia Trial in Germany (Venetoclax plus Azacitidine, standard of care chemo plus gemtuzumab ozogamicin)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Venetoclax plus Azacitidine
  • standard of care chemotherapy plus gemtuzumab ozogamicin
  • Essen, NRW, Germany
  • +17 more
Jun 6, 2023

Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Valhalla (Gemtuzumab Ozogamicin)

Active, not recruiting
  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndrome
  • Gemtuzumab Ozogamicin
  • Valhalla, New York
    New York Medical College
Sep 26, 2022

Acute Myeloid Leukemia Trial in Seattle (drug, biological, other)

Active, not recruiting
Has Results
  • Acute Myeloid Leukemia
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 10, 2022

Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia Trial in United States

Active, not recruiting
Has Results
  • Acute Myeloid Leukemia
  • +13 more
  • Burbank, California
  • +176 more
Mar 25, 2022

Acute Myeloid Leukemia Trial in Tampa (Vyxeos, Gemtuzumab Ozogamicin)

Recruiting
  • Acute Myeloid Leukemia
  • Tampa, Florida
    Moffitt Cancer Center
Sep 23, 2022

Lymphoma, B-Cell Trial in Worldwide (Inotuzumab ozogamicin [CMC-544])

Completed
Has Results
  • Lymphoma, B-Cell
  • Inotuzumab ozogamicin [CMC-544]
  • Birmingham, Alabama
  • +21 more
Dec 14, 2018

B-Cell Lymphoma Trial in Worldwide (inotuzumab ozogamicin, Rituximab)

Completed
Has Results
  • B-Cell Lymphoma
  • Birmingham, Alabama
  • +37 more
Feb 6, 2018

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Anti-OX40 Agonist Monoclonal Antibody

Active, not recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Anti-OX40 Agonist Monoclonal Antibody PF-04518600
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 25, 2022

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute

Recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +3 more
  • Gemtuzumab Ozogamicin
  • Liposome-encapsulated Daunorubicin-Cytarabine
  • Houston, Texas
    M D Anderson Cancer Center
Jun 2, 2021

Acute Lymphoblastic Leukemia Trial in Worldwide (inotuzumab ozogamicin, FLAG (fludarabine, cytarabine and G-CSF), HIDAC (high

Completed
Has Results
  • Acute Lymphoblastic Leukemia
  • inotuzumab ozogamicin
  • +3 more
  • La Jolla, California
  • +197 more
Dec 20, 2018

Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute

Recruiting
  • Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 27, 2021

Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Valhalla (Gemtuzumab Ozogamicin)

Active, not recruiting
  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndrome
  • Gemtuzumab Ozogamicin
  • Valhalla, New York
    New York Medical College
Nov 11, 2021